Ladenburg Thalmann Financial Services’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
$37K Buy
600
+500
+500% +$26.7K ﹤0.01% 3725
2019
Q3
$4K Hold
100
﹤0.01% 4749
2019
Q2
$5K Hold
100
﹤0.01% 4698
2019
Q1
$6K Hold
100
﹤0.01% 4572
2018
Q4
$4K Hold
100
﹤0.01% 4662
2018
Q3
$7K Hold
100
﹤0.01% 4431
2018
Q2
$6K Hold
100
﹤0.01% 4494
2018
Q1
$6K Hold
100
﹤0.01% 4494
2017
Q4
$6K Hold
100
﹤0.01% 4433
2017
Q3
$6K Sell
100
-157
-61% -$8.93K ﹤0.01% 4306
2017
Q2
$13K Buy
257
+77
+43% +$3.76K ﹤0.01% 3857
2017
Q1
$9K Sell
180
-120
-40% -$5.58K ﹤0.01% 4033
2016
Q4
$12K Hold
300
﹤0.01% 3766
2016
Q3
$15K Hold
300
﹤0.01% 3558
2016
Q2
$12K Buy
300
+200
+200% +$8.63K ﹤0.01% 3648
2016
Q1
$4K Sell
100
-491
-83% -$21.7K ﹤0.01% 4141
2015
Q4
$42K Buy
591
+383
+184% +$25.6K ﹤0.01% 2684
2015
Q3
$15K Sell
208
-702
-77% -$59.8K ﹤0.01% 3268
2015
Q2
$81K Buy
910
+710
+355% +$61.1K ﹤0.01% 2242
2015
Q1
$15K Buy
+200
New +$14.8K ﹤0.01% 3356

Other funds holding BIB

Ladenburg Thalmann Financial Services's BIB Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services increased its ProShares Ultra NASDAQ Biotechnology (BIB) stake by 500% in Q4 2019, buying an estimated $26.7K and bringing the position to 600 shares worth $37K. The position accounts for ﹤0.01% of the portfolio, ranked #3725.

Ladenburg Thalmann Financial Services first reported a position in BIB in Q1 2015 and has held it in 20 quarters since. The position peaked at $81K in Q2 2015. 26 funds tracked by Wall St. Rank hold BIB as of Q4 2019.

  • Ladenburg Thalmann Financial Services held 600 shares of ProShares Ultra NASDAQ Biotechnology worth $37K as of Q4 2019.
  • Ladenburg Thalmann Financial Services bought 500 ProShares Ultra NASDAQ Biotechnology shares in Q4 2019, an estimated $26.7K.
  • ProShares Ultra NASDAQ Biotechnology made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #3725 holding.
  • Ladenburg Thalmann Financial Services first reported a position in ProShares Ultra NASDAQ Biotechnology in Q1 2015 and has held it in 20 quarters since.
  • Ladenburg Thalmann Financial Services's ProShares Ultra NASDAQ Biotechnology position peaked at $81K in Q2 2015.
  • 26 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.